User profiles for M. Frick

Manfred Frick

Verified email at uni-ulm.de
Cited by 4434

[HTML][HTML] Food systems for sustainable development: proposals for a profound four-part transformation

…, N Divine, S Fan, M Frick, A Friis, M Gallagher… - Agronomy for …, 2018 - Springer
Evidence shows the importance of food systems for sustainable development: they are at
the nexus that links food security, nutrition, and human health, the viability of ecosystems, …

Heme oxygenase activity modulates vascular endothelial growth factor synthesis in vascular smooth muscle cells

…, A Józkowicz, R Foresti, A Kasza, M Frick… - … and Redox Signaling, 2002 - liebertpub.com
Hypoxia, cytokines, and nitric oxide (NO) stimulate the generation of vascular endothelial
growth factor (VEGF) and induce heme oxygenase-1 (HO-1) expression in vascular tissue. HO-…

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia

MH Frick, O Elo, K Haapa, OP Heinonen… - … England Journal of …, 1987 - Mass Medical Soc
In a randomized, double-blind five-year trial, we tested the efficacy of simultaneously elevating
serum levels of high-density lipoprotein (HDL) cholesterol and lowering levels of non-…

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for …

…, JK Huttunen, M Mänttäri, OP Heinonen, MH Frick - Circulation, 1992 - Am Heart Assoc
BACKGROUND We studied the joint effect of baseline triglyceride and lipoprotein cholesterol
levels on the incidence of cardiac end points in the trial group (n = 4,081) of the Helsinki …

Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study

V Manninen, MO Elo, MH Frick, K Haapa, OP Heinonen… - Jama, 1988 - jamanetwork.com
In the Helsinki Heart Study, a randomized five-year, double-blind trial, a 34% reduction in the
incidence of coronary heart disease (CHD) was observed in dyslipidemic men treated with …

Chronic Chlamydia pneumoniae Infection as a Risk Factor for Coronary Heart Disease in the Helsinki Heart Study

…, V Manninen, M Mänttäri, MH Frick… - Annals of internal …, 1992 - acpjournals.org
▪ Objective: To investigate in the prospective Helsinki Heart Study, whether chronic
Chlamydia pneumoniae infection, indicated by elevated antibody titers against the pathogen, …

[HTML][HTML] SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas

…, IM Wessbecher, M Frick, IG Costa, M Breunig… - Nature …, 2021 - nature.com
Infection-related diabetes can arise as a result of virus-associated β-cell destruction.
Clinical data suggest that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), …

Prevalence of hypogonadism in males aged at least 45 years: the HIM study

T Mulligan, MF Frick, QC Zuraw… - … journal of clinical …, 2006 - Wiley Online Library
… The odds ratio of having hypogonadism was 2.74 (95% CI, 2.07–3.07) in untreated patients
with a BMI ≥25 kg/m 2 vs. patients with a BMI <25 kg/m 2 . Men aged ≥65 years were 1.26 …

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

…, JK Huttunen, OP Heinonen, MH Frick - Diabetes …, 1992 - Am Diabetes Assoc
Objective To determine coronary heart disease (CHD) incidence among dyslipidemic subjects
with non-insulin-dependent diabetes mellitus (NIDDM) and to assess the effect of lipid-…

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind …

…, C Keil, A Schratter, M Frick, MA Benda, M Mächler… - The lancet, 2022 - thelancet.com
Background Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated coagulation …